Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 3rd Intercepting Blood Cancers (IBC) Workshop was held in Nice, France, on March 13-15, 2025. This workshop brought leading experts together to share insights into precursor conditions and early interventions in blood cancers.

The Intercepting Blood Cancers 2025 Workshop was supported by AbbVie, Johnson & Johnson, Regeneron, Sanofi, BeiGene, Eli Lilly & Company, and enduring content from IBC 2025 was supported by AstraZeneca. Supporters have no influence over the production of content.

IBC 2025

The 3rd Intercepting Blood Cancers (IBC) Workshop
13–15 March 2025 | Nice, France

IBC 2025

The 3rd Intercepting Blood Cancers (IBC) Workshop
13–15 March 2025 | Nice, France

The 3rd Intercepting Blood Cancers (IBC) Workshop was held in Nice, France, on March 13-15, 2025. This workshop brought leading experts together to share insights into precursor conditions and early interventions in blood cancers.

The Intercepting Blood Cancers 2025 Workshop was supported by AbbVie, Johnson & Johnson, Regeneron, Sanofi, BeiGene, Eli Lilly & Company, and enduring content from IBC 2025 was supported by AstraZeneca. Supporters have no influence over the production of content.

View all videos
2:34
Understanding the functional characterization of follicular lymphoma CPCs
Sandrine Roulland • 14 Mar 2025
1:29
The potential for early interception in MBL: advances and barriers
Anton Langerak • 14 Mar 2025
2:28
The genomic landscape of multiple myeloma and associated precursor conditions
Jean-Baptiste Alberge • 13 Mar 2025
1:55
Improving data collection to inform treatment decisions for patients with precursor conditions
Jenny Ahlstrom • 14 Mar 2025
Plenary Sessions and Keynote Lectures Multiple Myeloma/SMM/MGUS track MDS/CHIP/AML/CCUS track CLL/MBL/Lymphoma track

 

Plenary session 1: Classification

Jean-Baptiste Alberge
Genomic landscape of multiple myeloma and of its precursor conditions
Jean-Baptiste Alberge Dana-Farber Cancer Institute, Boston, MA, United States
José Ángel Martínez-Climent
Genetically-driven immune microenvironment landscapes across myeloma subtypes
José Ángel Martínez-Climent University of Navarra, Pamplona, Spain
Felipe Prósper
Non-genomic drivers of progression from MGUS to myeloma
Felipe Prósper University of Navarra, Navarra, Spain
Sanam Loghavi
Distinguishing CCUS & MDS – morphology or genes?
Sanam Loghavi The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Lourdes Mendez
CHIP and ALL – what do we know and what should we know?
Lourdes Mendez Yale School of Medicine, New Haven, CT, United States

 

Plenary session 2: Early detection, screening & risk stratification

Matteo Della Porta
AI & CHIP/CCUS opportunities
Matteo Della Porta Humanitas Research Hospital, Milan, Italy
Zhuoer Xie
Which prognostic tool to use for CHIP/CCUS? - Clonal cytopenia risk score (CCRS)
Zhuoer Xie Moffitt Cancer Center, Rochester, MN, United States
Mrinal Patnaik
Keynote talk: Emerging role for context relevant clonal hematopoiesis clinics in academic centers
Mrinal Patnaik Mayo Clinic, Rochester, MN, United States

 

Plenary session 3: To treat or not to treat?

Kwee Yong
Debate 1 – We should treat high-risk smoldering multiple myeloma and MGUS - Against
Kwee Yong University College London Hospitals NHS Foundation Trust, London, United Kingdom
George Vassiliou
Debate 2 – We should treat CHIP and CCUS - Against
George Vassiliou University of Cambridge, Cambridge, United Kingdom

 

Plenary session 4: Designing pre-cursor clinical trials

Elizabeth O'Donnell
The use of QoL & toxicity over time in precursor trials
Elizabeth O'Donnell Massachusetts General Hospital, Boston, MA, United States
Kenneth Anderson
Designing precursor clinical trials: MGUS/SMM/MM perspectives
Kenneth Anderson Dana-Farber Cancer Institute, Boston, MA, United States
Uma Borate
Good but not perfect: CCUS clinical trials – opportunities for incremental improvement
Uma Borate Ohio State University, Columbus, OH, United States
Paolo Ghia
Early interception in CLL: not yet ready to go?
Paolo Ghia Vita-Salute San Raffaele University, Milan, Italy
Jenny Ahlstrom
Decisions, debates and data: How precursor patients evaluate their options
Jenny Ahlstrom HealthTree Foundation, South Jordan , UT, United States

 

Plenary session 5: Defining response criteria

Irene Ghobrial
Defining new endpoints for clinical trials in smoldering myeloma
Irene Ghobrial Dana-Farber Cancer Institute, Boston, MA, United States
Zhuoer Xie
Relevant and achievable endpoints in CHIP and CCUS
Zhuoer Xie Moffitt Cancer Center, Rochester, MN, United States
Sameer Parikh
Novel endpoints for MBL/early-stage asymptomatic CLL
Sameer Parikh Mayo Clinic, Rochester, MN, United States

 

Plenary session 6: Latest from clinical trials I

Jesús San Miguel
Why should we intervene in precursor diseases
Jesús San Miguel University of Navarra, Navarra, Spain
Kenneth Anderson
Why an early timepoint of MRD would matter in SMM
Kenneth Anderson Dana-Farber Cancer Institute, Boston, MA, United States
Kelly Bolton
CDK4/6 inhibitors to prevent therapy-related TP53 CH expansion
Kelly Bolton Washington University in St. Louis, St. Louis, MO, United States
Petra Langerbeins
Update on early intervention in CLL
Petra Langerbeins University of Cologne, Cologne, Germany

 

Plenary session 7: Latest from clinical trials II

Carlyn Rose Tan
Contemporary translational projects in precursor plasma cell disorders
Carlyn Rose Tan Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Kwee Yong
Risk adapted approaches to intervention in SMM
Kwee Yong University College London Hospitals NHS Foundation Trust, London, United Kingdom
Ludovica Marando
Challenges and opportunities for early interventional trials in clonal hematopoiesis
Ludovica Marando Mayo Clinic, Rochester, MN, United States
Breakout summaries, outcomes and initiatives

 

Multiple myeloma/SMM/MGUS track

Catherine Marinac
Screening for monoclonal gammopathy: update on the PROMISE study
Catherine Marinac Dana-Farber Cancer Institute, Boston, MA, United States
Romanos Sklavenitis-Pistofidis
Immunological tools for assessing risk of disease progression
Romanos Sklavenitis-Pistofidis Dana-Farber Cancer Institute, Boston, MA, United States
Omar Nadeem
Utilizing PANGEA for risk stratification of MGUS and SMM
Omar Nadeem Dana-Farber Cancer Institute, Boston, MA, United States
Efstathios Kastritis
Risk stratification in SMM – the IMWG 2/20/20 model
Efstathios Kastritis National and Kapodistrian University of Athens, Athens, Greece
Adam Sperling
The use of biochemical progression as an endpoint
Adam Sperling Dana-Farber Cancer Institute, Boston, MA, United States
Nisha Joseph
The use of CR/MRD as an accelerated endpoint
Nisha Joseph Emory University School of Medicine, Atlanta, GA, United States
Hira Mian
Let’s agree to disagree: Reflections from the International Myeloma Society study summit on SMM
Hira Mian McMaster University, Hamilton, Canada
Omar Nadeem
Phase II trials and immunotherapy approaches in SMM
Omar Nadeem Dana-Farber Cancer Institute, Boston, MA, United States
Urvi Shah
Non-drug interventions in SMM/MGUS: diet and lifestyle
Urvi Shah Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Meletios Dimopoulos
Which treatment should you choose for your high-risk SMM patient? Daratumumab?
Meletios Dimopoulos University of Athens School of Medicine, Athens, Greece

 

CHIP/CCUS/MDS/AML track

Jamie Blundell
Does the immune system recognize clonal hematopoiesis mutations?
Jamie Blundell University of Cambridge, Cambridge, United Kingdom
Uma Borate
Targeting the inflammasome in high-risk clonal hematopoiesis
Uma Borate Ohio State University, Columbus, OH, United States
David Steensma
What we can learn about clonal hematopoiesis from large interventional studies
David Steensma Ajax Therapeutics, Cambridge, MA, United States
Kelly Bolton
Use of ivosidenib in IDH1-mutant CCUS: clinical trial updates
Kelly Bolton Washington University in St. Louis, St. Louis, MO, United States

 

CLL/MBL/Lymphoma track

Sandrine Roulland
Deciphering and intercepting follicular lymphoma clonal precursor cells
Sandrine Roulland Centre d'Immunologie Marseille-Luminy (CIML), Marseille, France
Aswin Sekar
Enabling large-scale studies of high-count MBL using existing data in biobanks
Aswin Sekar Dana-Farber Cancer Institute, Boston, MA, United States
Anton Langerak
Novel testing approaches for the early detection of suspected lymphoproliferative disorders
Anton Langerak Erasmus University Medical Center, Rotterdam, Netherlands
Carsten Niemann
Updates on machine learning and early intervention strategies
Carsten Niemann Copenhagen University Hospital, Copenhagen, Denmark

The content of VJHemOnc is intended for healthcare professionals